Eli Lilly and Company (@EliLillyandCo)
@EliLillyandCo
Uniting caring with discovery to create medicines that make life better worldwide. Lilly’s official account (formerly LillyPad)
1.2K 正在关注 144.9K 粉丝
🚨 Our investigational triple agonist helped people lose weight, but that’s not all according to data shared at ADA 2026. See more about the obesity-related conditions it helped in our study.
We’re heading to ADA 2026 with exciting scientific data. Give this post a ❤️ to receive our updates and learn how the data could impact the future of obesity and diabetes care.
Millions of Americans may soon have broader coverage for Lilly’s obesity medicines.
We’ve announced new data from the latest Phase 3 study of retatrutide, an investigational triple hormone receptor agonist.
Why is it so hard to maintain long-term weight loss? Biology.
